See more : NextEra Energy, Inc. (NEE-PR) Income Statement Analysis – Financial Results
Complete financial analysis of Hainan Shuangcheng Pharmaceuticals Co., Ltd. (002693.SZ) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Hainan Shuangcheng Pharmaceuticals Co., Ltd., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Valneva SE (0OB3.L) Income Statement Analysis – Financial Results
- Aspo Oyj (ASPO.HE) Income Statement Analysis – Financial Results
- Koninklijke KPN N.V. (KKPNY) Income Statement Analysis – Financial Results
- Mitsui O.S.K. Lines, Ltd. (9104.T) Income Statement Analysis – Financial Results
- Kridhan Infra Limited (KRIDHANINF.NS) Income Statement Analysis – Financial Results
Hainan Shuangcheng Pharmaceuticals Co., Ltd. (002693.SZ)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.shuangchengmed.com
About Hainan Shuangcheng Pharmaceuticals Co., Ltd.
Hainan Shuangcheng Pharmaceuticals Co., Ltd. researches, develops, manufactures, and markets synthesized peptide drugs and active pharmaceutical ingredients worldwide. It offers somatostatin, thymosin, clindamycin hydrochloride, thymopentin, L-carnitine, uranin hydrobromide, inosine, cyclophosphine adenosine, motidine, scopolamine, and sodium ferulate for injections, as well as vitamin B6. The company was founded in 2000 and is based in Haikou, the People's Republic of China.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 235.93M | 274.75M | 320.29M | 269.44M | 346.65M | 337.24M | 246.77M | 145.14M | 230.97M | 161.20M | 149.60M | 129.66M | 133.50M | 112.88M | 88.18M |
| Cost of Revenue | 82.41M | 88.29M | 81.39M | 60.18M | 95.11M | 120.86M | 91.46M | 69.93M | 102.14M | 55.92M | 52.77M | 37.14M | 33.70M | 28.35M | 28.94M |
| Gross Profit | 153.52M | 186.47M | 238.91M | 209.26M | 251.54M | 216.39M | 155.31M | 75.20M | 128.84M | 105.28M | 96.84M | 92.53M | 99.81M | 84.53M | 59.24M |
| Gross Profit Ratio | 65.07% | 67.87% | 74.59% | 77.66% | 72.56% | 64.16% | 62.94% | 51.82% | 55.78% | 65.31% | 64.73% | 71.36% | 74.76% | 74.88% | 67.18% |
| Research & Development | 14.93M | 14.59M | 10.62M | 12.18M | 13.14M | 14.53M | 14.68M | 70.91M | 11.32M | 12.32M | 9.22M | 2.36M | 5.28M | 2.10M | 3.68M |
| General & Administrative | 72.26M | 11.81M | 13.55M | 15.34M | 12.07M | 16.54M | 12.95M | 13.98M | 14.67M | 9.06M | 8.45M | 4.95M | 4.61M | 3.07M | 2.50M |
| Selling & Marketing | 102.97M | 126.20M | 189.54M | 167.47M | 205.97M | 184.62M | 104.94M | 35.84M | 16.50M | 18.84M | 11.46M | 6.34M | 5.47M | 5.35M | 11.46M |
| SG&A | 176.38M | 138.02M | 203.09M | 182.81M | 218.05M | 201.16M | 117.89M | 49.82M | 31.16M | 27.91M | 19.91M | 11.29M | 10.08M | 8.42M | 13.96M |
| Other Expenses | 0.00 | 63.18M | 68.97M | 69.66M | 41.49M | -3.13M | 2.21M | 4.22M | 5.08M | -440.03K | 3.50M | 6.63M | 2.52M | 615.31K | 912.53K |
| Operating Expenses | 219.70M | 215.79M | 282.67M | 264.65M | 272.67M | 283.81M | 182.94M | 179.26M | 73.35M | 54.20M | 41.97M | 26.52M | 23.64M | 15.06M | 20.75M |
| Cost & Expenses | 302.11M | 304.08M | 364.06M | 324.83M | 367.78M | 404.67M | 274.39M | 249.19M | 175.49M | 110.12M | 94.73M | 63.66M | 57.33M | 43.42M | 49.69M |
| Interest Income | 34.48K | 61.66K | 53.20K | 89.31K | 550.54K | 261.43K | 256.26K | 192.71K | 885.82K | 4.98M | 7.88M | 6.18M | 1.64M | 270.28K | 28.49K |
| Interest Expense | 9.58M | 11.19M | 9.03M | 10.01M | 9.83M | 17.54M | 16.59M | 15.27M | 16.05M | 4.63M | 44.36K | 40.89K | 32.49K | 7.80K | 277.77K |
| Depreciation & Amortization | 54.05M | 58.52M | 55.49M | 58.29M | 60.31M | 57.31M | 45.03M | 31.41M | 20.68M | 17.38M | 12.61M | 7.58M | 5.67M | 5.00M | 3.65M |
| EBITDA | -9.30M | 60.88M | 24.97M | -10.06M | 81.11M | -19.69M | 60.05M | -346.12M | 90.06M | 70.66M | 67.48M | 73.59M | 80.02M | 76.69M | 43.07M |
| EBITDA Ratio | -3.94% | 12.03% | 3.75% | 1.45% | 13.06% | -4.71% | 27.70% | -43.28% | 43.36% | 42.55% | 45.10% | 56.63% | 64.34% | 67.94% | 48.84% |
| Operating Income | -36.83M | -24.48M | -42.32M | -53.20M | -13.74M | -90.24M | 867.88K | -389.08M | 57.42M | 69.66M | 75.15M | 73.33M | 77.94M | 71.55M | 38.75M |
| Operating Income Ratio | -15.61% | -8.91% | -13.21% | -19.74% | -3.96% | -26.76% | 0.35% | -268.08% | 24.86% | 43.21% | 50.23% | 56.55% | 58.38% | 63.38% | 43.94% |
| Total Other Income/Expenses | -36.13M | 15.60M | 1.97M | -18.43M | 2.63M | -18.84M | 2.21M | -280.31M | -7.47M | 18.06M | 23.74M | 6.62M | 2.07M | 2.22M | -3.12M |
| Income Before Tax | -72.97M | -8.88M | -40.36M | -78.78M | 10.52M | -93.36M | 3.08M | -385.08M | 62.28M | 69.11M | 78.63M | 79.95M | 80.02M | 72.16M | 35.89M |
| Income Before Tax Ratio | -30.93% | -3.23% | -12.60% | -29.24% | 3.03% | -27.68% | 1.25% | -265.32% | 26.96% | 42.87% | 52.56% | 61.66% | 59.94% | 63.93% | 40.70% |
| Income Tax Expense | -991.59K | -384.96K | 449.95K | 1.17M | 1.49M | -1.22M | 1.75M | 3.33M | 9.60M | 10.18M | 11.86M | 11.95M | 9.60M | 7.93M | 3.79M |
| Net Income | -50.74M | -8.50M | -40.81M | -79.95M | 9.03M | -69.46M | 6.31M | -388.41M | 52.68M | 58.93M | 66.77M | 68.00M | 70.41M | 64.23M | 32.11M |
| Net Income Ratio | -21.51% | -3.09% | -12.74% | -29.67% | 2.60% | -20.60% | 2.56% | -267.62% | 22.81% | 36.56% | 44.63% | 52.44% | 52.74% | 56.90% | 36.41% |
| EPS | -0.12 | -0.02 | -0.10 | -0.20 | 0.02 | -0.17 | 0.02 | -0.96 | 0.13 | 0.15 | 0.17 | 0.19 | 0.23 | 0.21 | 1.90 |
| EPS Diluted | -0.12 | -0.02 | -0.10 | -0.20 | 0.02 | -0.17 | 0.02 | -0.96 | 0.13 | 0.15 | 0.17 | 0.19 | 0.23 | 0.21 | 1.90 |
| Weighted Avg Shares Out | 422.85M | 410.54M | 405.00M | 405.00M | 405.00M | 405.00M | 315.74M | 404.59M | 405.00M | 405.20M | 400.55M | 364.21M | 304.67M | 305.32M | 412.00M |
| Weighted Avg Shares Out (Dil) | 422.85M | 410.54M | 405.00M | 405.00M | 405.00M | 408.56M | 315.74M | 404.59M | 405.22M | 405.20M | 400.63M | 364.28M | 304.67M | 305.32M | 412.00M |
Source: https://incomestatements.info
Category: Stock Reports